Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol for CNS Hemangioblastomas in VHL
NCT05424016Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of propranolol in hemangioblastoma (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Total and individual hemangioblastomas' volume at 24 months. Started Jan 2023; status: recruiting.
02
Drugs
propranolol
03
Conditions
hemangioblastoma
Beyond the preview
Go deeper on NCT05424016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05424016.